Expert Committee Asks To Remove 'Trial Mode' Label From Covaxin

The Centre’s Subject Expert Committee has recommended to remove the "clinical trial mode" label from the Bharat Biotech’s COVID-19 vaccine, Covaxin. Reportedly, if the recommendation is considered by the Drugs Controller General of India, it will boost the usage of the vaccine. The recommendation came after Covaxin showed 80.6% efficiency in the late-stage clinical trials. The DCGI’s nod will also not require patients to sign consent form before taking the vaccine in trial mode.